The cost-effectiveness of a hypothetical respiratory syncytial virus vaccine in the elderly

Vaccine

Volumn 18, Issue 15, 2000, Pages 1485-1494

  Gessner, Bradford D ^a  

^a Assoc pour l'Aide a la Medecine P   (France)

Author keywords

Cost effectiveness; Respiratory syncytial virus; Vaccine

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE;

AGED; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HOSPITALIZATION; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VACCINATION;

AGE FACTORS; AGED; COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; HUMANS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL VACCINES;

EID: 0033984192     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00425-9     Document Type: Conference Paper

References (69)

1. Falsey A.R., Cunningham C.K., Barker W.H., Kouides R.W., Yuen J.B., Menegus M., et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infec. Dis. 172:1995;389-394.
2. Falsey A.R., Treanor J.J., Betts R.F., Walsh E.E. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J. Am. Geriatr. Soc. 40:1992;115-119.
3. Dowell S.F., Anderson L.J., Gary H.E., Erdman D.D., Plouffe J.F., File T.M., et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infec. Dis. 174:1996;456-462.
4. Mlinaric-Galinovic G., Falsey A.R., Walsh E.E. Respiratory syncytial virus infection in the elderly. Eur. J. Clin. Microbiol. Infect. Dis. 15:1996;777-781.
5. Falsey A.R., McCann R.M., Hall W.J., Tanner M.A., Criddle M.M., Formica M.A., et al. Acute respiratory tract infection in daycare centers for older persons. J. Am. Geriatr. Soc. 43:1995;30-36.
6. Nicholson K.G., Kent J., Hammersley V., Cancio E. Acute viral infections of upper respiratory tract in elderly people living in the community: comparative, prospective, population based study of disease burden. BMJ. 315:1997;1060-1064.
7. Wald T.G., Miller B.A., Shult P., Drinka P., Langer L., Gravenstein S. Can respiratory syncytial virus and influenza A be distinguished clinically in institutionalized older persons? J. Am. Geriatr. Soc. 43:1995;170-174.
8. MacFarlane J.T., Colville A., Guion A., MacFarlane R.M., Rose D.H. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. Lancet. 341:1993;511-514.
9. Mathur U., Bentley D.W., Hall C.B. Concurrent respiratory syncytial virus and influenza A infections in the institutionalized elderly and chronically ill. Ann. Int. Med. 93:1980;49-52.
10. Murry AR, Dowell SF. Respiratory syncytial virus: not just for kids. Hosp Prac 1997;32:87-8, 91-4, 98.
11. Fleming D.M., Cross K.W. Respiratory syncytial virus or influenza? Lancet. 342:1993;1507-1510.
12. Murphy B.R., Collins P.L. Current status of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccine development: memorandum from a joint WHO/NIAID meeting. Bull. World Health Org. 75:1997;307-313.
13. Gross P.A., Hermogenes A.W., Lau J., Levandowski R.A. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann. Int. Med. 123:1995;518-527.
14. Nichol K.L., Margolis K.L., Wuorenma J., Von Sternberg T.V. The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community. N. Engl. J. Med. 331:1994;778-784.
15. Monto A.S., Terpenning M.S. The value of influenza and pneumococcal vaccines in the elderly. Drugs Aging. 8:1996;445-451.
16. Nichol K.L., Margolis K.L., Wouremna J., von Sternberg T. Effectiveness of influenza vaccine in the elderly. Gerontology. 42:1996;274-279.
17. Sisk J.E., Moskowitz A.M., Whang W., Lin J.D., Fedson D.S., McBean A.M., et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA. 278:1997;1333-1339.
18. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices (ACIP). Morb. Mort. Wkly Rep. 46:(RR-8):1997;1-24.
19. Statistical abstract of the US, 1997, Table No. 16: Resident population by sex and age: 1996. Bureau of Labor Statistics.
20. Hall C.B., Walsh E.E., Long C.E., Schnabel K.C. Immunity to and frequency of reinfection with respiratory syncytial virus. J. Infect. Dis. 163:1991;693-698.
21. Falsey A.R., Walsh E.E. Humoral immunity to respiratory syncytial virus infection in the elderly. J. Med. Virol. 36:1992;39-43.
22. Johnson K., Bloom H.H., Mufson M.A., Chanock R.M. Natural reinfection of adults by respiratory syncytial virus: possible relation to mild upper respiratory disease. N. Engl. J. Med. 267:1962;68-72.
23. Hall C.B., Geiman J.M., Biggar R., Kotok D.I., Hogan P.M., Douglas G.R. Jr. Respiratory syncytial virus infections within families. N. Engl. J. Med. 294:1976;414-419.
24. Henderson F.W., Collier A.M., Clyde W.A. Jr., Denny F.W. Respiratory-syncytial-virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N. Engl. J. Med. 300:1979;530-534.
25. Glezen W.P., Taber L.H., Frank A.L., Kasel J.A. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140:1986;543-546.
26. Fedson D.S., Wajda A., Nicol J.P., Roos L.L. The old man's friend. Lancet. 342:1993;561.
27. Brancati F.L., Chow J.W., Wagener M.M., Vacarello S.J., Yu V.L. Is pneumonia really the old man's friend? Two-year prognosis after community-acquired pneumonia. Lancet. 342:1993;30-33.
28. Economic report of the President. 1997;365 US Government Printing Office, Washington, DC.
29. Laschober MA, Olin GL. Health and health care of the medicare population: data from the 1992 Current Beneficiary Survey. Rockville, MD: Westat, 1996. p. 44, 133, 136.
30. Gold M.R., Siegel J.E., Russell L.B., Weinstein M.C. Cost-effectiveness in health and medicine. 1996;Oxford University Press, New York, NY.
31. National Center for Health Statistics. Table 29: Life expectancy at birth, at 65 years of age, and at 75 years of age, according to race and sex: United States, selected years 1900-95. Health, United States, 1996-97 and Injury Chartbook. Hyattsville, MD, 1997. p. 108.
32. Erickson P., Wilson R., Shannon I. Years of health life. Stat. Notes. 7:1995;1-14.
33. Falsey A.R., McCann R.M., Hall W.J., Criddle M.M. Evaluation of four methods for the diagnosis of respiratory syncytial virus infection in older adults. J. Am. Geriatr. Soc. 44:1996;71-73.
34. Jackson M.M., Fierer J., Barrett-Connor E., Fraser D., Klauber M.R., Hatch R., et al. Intensive surveillance for infections in a three-year study of nursing home patients. Am. J. Epidemiol. 135:1992;685-696.
35. Ortqvist A., Hedlund J., Grillner L., Jalonen E., Kallings I., Leinonen M., et al. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization. Eur. Resp. J. 3:1990;1105-1113.
36. Marston B.J., Plouffe J.F., File T.M., Hackman B.A., Salstrom S.J., Lipman H.B., et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch. Int. Med. 157:1997;1709-1718.
37. Garibaldi R.A. Epidemiology of community-acquired respiratory tract infections in adults; incidence, etiology and impact. Am. J. Med. 78:(6B):1985;32-37.
38. National Center for Health Statistics. Table 88. Rates of discharges and days of care in non-Federal short-stay hospitals, according to sex, age, and selected first-listed diagnosis: United States, 1985, 1990, 1994 and 1995. Health, United States, 1996-97 and Injury Chartbook. Hyattsville, MD, 1997. p. 211-3.
39. Han L.L., Alexander J.P., Anderson L.J. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J. Infec. Dis. 179:1999;25-30.
40. Gonzales R., Steiner J.F., Sande M.A. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians. JAMA. 278:1997;901-904.
41. Mainous A.G., Zoorob R.J., Hueston W.J. Current management of acute bronchitis in ambulatory care: the use of antibiotics and bronchodilators. Arch. Fam. Med. 5:1996;79-83.
42. Mainous A.G., Hueston W.J., Clark J.R. Antibiotics and upper respiratory infection: do some folks think there is a cure for the common cold. J. Fam. Pract. 42:1996;357-361.
43. Agius G., Dindinaud G., Biggar R.J., Peyre R., Vaillant V., Ranger S., et al. An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings. J. Med. Virol. 30:1990;117-127.
44. Vikerfors T., Grandien M., Olcen P. Respiratory syncytial virus infections in adults. Am. Rev. Respir. Dis. 136:1987;561-564.
45. Nicholson K.G., Baker D.J., Farquar A., Hurd D., Kent J., Smith S.H. Acute upper respiratory tract viral illness and influenza immunization in homes for the elderly. Epidemiol. Infect. 105:1990;609-618.
46. Statistical abstract of the US, 1997, Table 752: Consumer price indexes, by major groups: 1939 to 1996.
47. Mulhooly J.P., Bennett M.D., Hornbrook M.C., Barker W.H., Williams W.W., Patriarca P.A., et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann. Int. Med. 121:1994;947-952.
48. Current procedural terminology. 1998;American Medical Association.
49. McBean A.M., Babish J.D., Warren J.L. The impact and cost of influenza in the elderly. Arch. Int. Med. 153:1993;2105-2111.
50. Lave J.R., Fine M.J., Steadman S.S., Hanusa B.H., Weissfeld L.A., Kapoor W.N. Hospitalized pneumonia: outcomes, treatment patterns, and costs in urban and rural areas. J. Gen. Int. Med. 11:1996;415-421.
51. National Center for Health Statistics. Table 128: Nursing home average monthly charges per resident and percent of residents, according to primary source of payments and selected facility characteristics: United States, 1977 and 1985. Health, United States, 1996-97 and Injury Chartbook. Hyattsville, MD, 1997. p. 262.
52. Hampson A.W., Irving L.B. Influenza vaccination: cost-effective health care for the older adult? J. Qual. Clin. Pract. 17:1997;3-11.
53. Pneumococcal and influenza vaccination levels among adults aged > or=65 years - United States, 1993. MMWR Morb. Mortal. Wkly Rep. 45:1996;853-859.
54. Fedson D.S. Influenza and pneumococcal vaccination of the elderly: newer vaccines and prospects for clinical benefits at the margin. Prev. Med. 23:1994;751-755.
55. McKesson Item Catalog. McKesson Drug Company, San Francisco CA, 1997.
56. US Congress, Office of Technology Assessment. The costs and effectiveness of colorectal cancer screening in the elderly. Washington, DC: US Government Printing Office, 1990.
57. Tengs T.O., Adams M.E., Pliskin J.S., Safran D.G., Siegel J.E., Weinstein M.C., Graham J.D. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal. 15:1995;369-390.
58. Laupacis A., Feeny D., Detsky A.S., Tugwell P.X. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can. Med. Assoc. J. 146:1992;473-481.
59. Classen D.C., Pestotnik S.L., Evans R.S., Lloyd J.F., Burke J.P. Adverse drug events in hospitalized patients: excess length of stay, extra costs and attributable mortality. JAMA. 277:1997;301-306.
60. Lazarou J., Pomeranz B.H., Corey P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 279:1998;1200-1205.
61. Jokinen C., Heiskanen L., Juvonen H., Kallinen S., Karkola K., Korppi M., et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am. J. Epidemiol. 137:1993;977-988.
62. Nichol K.L., Mendelman P.M., Mallon K.P., Jackson L.A., Gorse G.J., Belshe R.B., et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. JAMA. 282:1999;137-144.
63. Falsey A.R., Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine. 14:1996;1214-1218.
64. Falsey A.R., Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine. 15:1997;1130-1132.
65. Dudas R.A., Karron R.A. Respiratory syncytial virus vaccines. Clin. Microbiol. Rev. 11:1998;430-439.
66. Karron R.A., Wright P.F., Crowe J.E. Jr., Clements-Mann M.L., Thompson J., Makhene M., et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants and children. J. Infect. Dis. 176:1997;1428-1436.
67. Higuera F., Hidalgo H., Feris J., Giguere G., Collins J.J. Comparison of oral cefuroxime axetil and oral amoxicillin/clavulanate in the treatment of community-acquired pneumonia. J. Antimicrob. Chemother. 37:1996;555-564.
68. Cunha B.A. The antibiotic treatment of community-acquired, atypical and nosocomial pneumonias. Med. Clin. North Am. 79:1995;581-597.
69. National Center for Health Statistics. Table 34: Leading causes of death and numbers of deaths, according to age: United States, 1980 and 1995. Health, United States, 1996-97 and Injury Chartbook. Hyattsville, MD, 1997. p. 121-2.